Recent Blog Articles
Screening at home for memory loss: Should you try it?
Travel tummy troubles: Here’s how to prevent or soothe them
Easy, delicious summer veggie meals will help stretch your food budget
Tracking viruses: The best clues may be in the sewer
Promising therapy if PSA rises after prostate cancer surgery
Strong legs help power summer activities: Hiking, biking, swimming, and more
Should you try intermittent fasting for weight loss?
Why are you taking a multivitamin?
Could eating fish increase your risk of cancer?
Can music improve our health and quality of life?
How to spell pain relief in the wake of COX-2 problems
Taking drugs of any kind is never without risks, but setbacks surrounding the vigorously marketed COX-2 inhibitors have really brought this home.
It's been tough going for pain relievers since the pharmaceutical company Merck pulled its COX-2 inhibitor rofecoxib (Vioxx) from the market in fall 2004, valdecoxib (Bextra) was pulled in March 2005, and the one remaining COX-inhibitor, celecoxib (Celebrex), was also found to have cardiovascular risks.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
Free Healthbeat Signup
Get the latest in health news delivered to your inbox!
